COLOSPAN LTD

Galmed Pharmaceuticals to Acquire Colospan, Creating GI-Focused Medtech Platform Targeting $6 Billion Colorectal Surgery Market

- Galmed Pharmaceuticals entered a definitive agreement to acquire Colospan Ltd., a commercial-stage medical device company focused on colorectal surgery complications. - Colospan's CG-100 intraluminal bypass device holds FDA Breakthrough Device Designation and CE mark, designed to reduce anastomotic leaks and eliminate the need for diverting stomas. - Galmed plans a $6 million investment to launch CG-100 commercially in Germany, Austria, and Switzerland during the second half of 2026. - The transaction, valued at $4.5 million in cash and shares, is expected to close in Q2 2026 pending customary conditions.